KMT2C mutations have been detected in a variety of tumors, including hepatocellular carcinoma (30), breast cancer (31), colon cancer (32), bladder cancer (33), myelodysplastic syndromes and acute myeloid leukemia (AML) (34). Here, KMT2C is linked to hepatocellular carcinoma.